Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)

By Tran Hai   Zinner Ralph   Blumenschein George   Oh Yun   Papadimitrakopoulou Vassiliki   Kim Edward   Lu Charles   Malik Mubashira   Lum Bert   Herbst Roy  

Investigational New Drugs, Vol. 29, Iss. 3, 2011-06 ,pp. : 499-505

Springer Publishing Company

Access to resources Recommend Favorite

A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma

By Li Ning   Ou Wei   Yang Hua   Liu Qian-Wen   Zhang Song-Liang   Wang Bao-Xiao   Wang Si-Yu  

Cancer, Vol. 120, Iss. 9, 2014-05 ,pp. : 1379-1386

Blackwell Publishing

Access to resources Recommend Favorite

Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer: Phase 3 randomized trial

By  

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3412-3421

Blackwell Publishing

Access to resources Recommend Favorite

Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)

By Israel Valerie   Tagawa Scott   Snyder Terry   Jeffers Susan   Raghavan Derek  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 291-297

Springer Publishing Company

Access to resources Recommend Favorite

Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer

By Ho Cheryl   Davies Angela   Sangha Randeep   Lau Derick   Lara Primo   Chew Helen   Beckett Laurel   Mack Philip   Riess Jonathan   Gandara David  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1587-1591

Springer Publishing Company

Access to resources Recommend Favorite